Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A proof-of Concept Study of the Use of Janus Kinase 1 and 2 Inhibitor, Baricitinib, in the Treatment of COVID-19-related Pneumonia

NCT04399798 is registered in ClinicalTrials.gov with Fondazione IRCCS Policlinico San Matteo di Pavia as lead sponsor.

NCT NCT04399798
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04399798 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A proof-of Concept Study of the Use of Janus Kinase 1 and 2 Inhibitor, Baricitinib, in the Treatment of COVID-19-related Pneumonia
Lead sponsor
Fondazione IRCCS Policlinico San Matteo di Pavia
Phase
Phase 2
Overall status
Unknown status
Start date
May 15, 2020
Completion date
November 15, 2020
Enrollment
13 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

corona virus infection